1. Home
  2. Directory
  3. Minnesota
  4. Minneapolis
  5. Physician Assistant
  6. NPI Profile
  7. Prescriptions 1194355065

MS. JULIA NOELLE COLLING PA-C
Prescription History 1194355065
Physician Assistant in Minneapolis, MN


Quality Rating: 81.72 out of 100 score

NPI Status: Active since January 20, 2020

Contact Information

2512 S 7TH ST # 105
MINNEAPOLIS, MN
ZIP 55454
Phone: (612) 273-5005

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MS. JULIA NOELLE COLLING PA-C, an active Physician Assistant specialist practicing in Minneapolis, MN. Our medical registry currently tracks 6 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 227 documented patient claims. Among these therapy options, the most frequently utilized medication is Xarelto, which accounts for 74 claims alone.

Medication Index

C
E
F
T
W
X
No matching medications currently found on file.

Celecoxib

Generic Formulation: CelecoxibSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 40
30-Day Fills 58.0
Days Supply 1,740
MN State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills47.6
Peer Average Days Supply1,363
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 48.1% more claims than the standard regional baseline profile for MN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,808.22 across this reporting matrix range.

Provider Avg Cost Per Claim

$70.21

State Avg Cost Per Claim

$57.33

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrazole derivative and selective CYCLOOXYGENASE 2 INHIBITOR that is used to treat symptoms associated with RHEUMATOID ARTHRITIS; OSTEOARTHRITIS and JUVENILE ARTHRITIS, as well as the management of ACUTE PAIN.

Therapeutic Applications

This medication is a nonsteroidal anti-inflammatory drug (NSAID), specifically a COX-2 inhibitor, which relieves pain and swelling (inflammation). It is used to treat arthritis, acute pain, and menstrual pain and discomfort. The pain and swelling relief provided by this medication helps you perform more of your normal daily activities. If you are treating a chronic condition such as arthritis, ask your doctor about non-drug treatments and/or using other medications to treat your pain. See also Warning section. This drug works by blocking the enzyme in your body that makes prostaglandins. Decreasing prostaglandins helps to reduce pain and swelling.

Eliquis

Generic Formulation: ApixabanSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 70
30-Day Fills 102.3
Days Supply 3,035
MN State Average Benchmarks
Peer Average Claims53.0
Peer Average 30-Day Fills91.9
Peer Average Days Supply2,594
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 32.1% more claims than the standard regional baseline profile for MN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $57,319.64 across this reporting matrix range.

Provider Avg Cost Per Claim

$818.85

State Avg Cost Per Claim

$877.44

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Fondaparinux Sodium

Generic Formulation: Fondaparinux SodiumSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 285
MN State Average Benchmarks
Peer Average Claims15.0
Peer Average 30-Day Fills16.4
Peer Average Days Supply481
Conservative Utilization

This provider writes prescriptions for this formulation 26.7% less frequently than the standard regional baseline metric for practitioners inside MN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $12,511.57 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,137.42

State Avg Cost Per Claim

$2,346.78

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Synthetic pentasaccharide that mediates the interaction of HEPARIN with ANTITHROMBINS and inhibits FACTOR Xa; it is used for prevention of VENOUS THROMBOEMBOLISM after surgery.

Therapeutic Applications

Fondaparinux is used to treat serious blood clots in the legs and/or lungs. It is usually used with another blood thinner medication (warfarin). If untreated, blood clots can travel to the lungs, heart, or brain, causing serious (possibly fatal) breathing problems, heart attack, or stroke. This drug may also be used to prevent blood clots after certain surgeries with an increased risk of blood clots (such as hip fracture, abdominal, knee/hip replacement). Fondaparinux is known as a blood thinner (anticoagulant). It is a drug similar to heparin that works by blocking certain natural substances in the blood that cause clotting.

Tranexamic Acid

Generic Formulation: Tranexamic AcidSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 327
MN State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills20.5
Peer Average Days Supply325
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,282.62 across this reporting matrix range.

Provider Avg Cost Per Claim

$193.10

State Avg Cost Per Claim

$244.46

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Antifibrinolytic hemostatic used in severe hemorrhage.

Warfarin Sodium

Generic Formulation: Warfarin SodiumSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 15
30-Day Fills 29.3
Days Supply 880
MN State Average Benchmarks
Peer Average Claims60.0
Peer Average 30-Day Fills122.1
Peer Average Days Supply3,239
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 75.0% less volume than the regional standard for practitioners inside MN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $324.30 across this reporting matrix range.

Provider Avg Cost Per Claim

$21.62

State Avg Cost Per Claim

$13.09

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.

Therapeutic Applications

This medication is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and/or to prevent new clots from forming in your body. Preventing harmful blood clots helps to reduce the risk of a stroke or heart attack. Conditions that increase your risk of developing blood clots include a certain type of irregular heart rhythm (atrial fibrillation), heart valve replacement, recent heart attack, and certain surgeries (such as hip/knee replacement). Warfarin is commonly called a blood thinner, but the more correct term is anticoagulant. It helps to keep blood flowing smoothly in your body by decreasing the amount of certain substances (clotting proteins) in your blood.

Xarelto

Generic Formulation: RivaroxabanSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 74
30-Day Fills 128.0
Days Supply 3,790
MN State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills64.9
Peer Average Days Supply1,855
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 117.6% higher than the standard regional baseline profile for MN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $72,660.41 across this reporting matrix range.

Provider Avg Cost Per Claim

$981.90

State Avg Cost Per Claim

$960.12

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.

Therapeutic Applications

Rivaroxaban is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. It is also used to prevent blood clots from forming in high-risk patients with limited mobility during their hospital stay and after discharge. In addition, rivaroxaban is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and to prevent the blood clots from forming again. Rivaroxaban may be used in children to prevent blood clots from forming after a certain heart surgery (Fontan procedure). Rivaroxaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MS. JULIA NOELLE COLLING PA-C provides transparency into local medical care patterns within Minneapolis, MN.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Physician Assistant** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.